Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of XEN1101 in adults with epilepsy
MOH_2023-09-12_012932Phase 3Not yet recruiting
- Sponsor
- Xenon Pharmaceuticals
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of azetukalner in epilepsy, Focal onset seizure and primary generalized tonic-clonic seizure (PGTCS), sponsored by Xenon Pharmaceuticals. Primary endpoint: Safety and tolerability of long-term XEN1101 treatment. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
azetukalner
03
Conditions
epilepsyFocal onset seizureprimary generalized tonic-clonic seizure (PGTCS)
Beyond the preview
Go deeper on MOH_2023-09-12_012932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-09-12_012932.